Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 9.8% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a biotechnology company specializing in CRISPR/Cas9-based therapies for genetic diseases. The company has recently provided updates on its clinical programs.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 9.8% on May 14, 2026 19:40

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Intellia Therapeutics (NASDAQ: NTLA) reported first-quarter results that surpassed analyst expectations, with revenues of US$15m beating forecasts by 9.0% and statutory losses being 9.0% smaller than anticipated. Following these results, analysts maintained their revenue forecasts for 2026 at US$60.4m but moderately upgraded their loss per share forecasts to US$3.25, suggesting an improvement in sentiment. The average price target remained steady at US$26.65, though there is a wide spread in analyst valuations, indicating divergent views on the company's future performance.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/earnings-update-intellia-therapeutics-inc-nasdaqntla-just-re

Wedbush Remains a Hold on Intellia Therapeutics (NTLA)

Wedbush maintained a Hold rating on Intellia Therapeutics (NTLA) with a $12.00 price target. The company reported a quarterly revenue of $23.02 million and a GAAP net loss of $95.79 million. Insider sentiment is negative, with an increase in share sales by corporate insiders over the past quarter.

https://www.theglobeandmail.com/investing/markets/stocks/NTLA-Q/pressreleases/1906937/wedbush-remains-a-hold-on-intellia-therapeutics-ntla/

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline

Intellia Therapeutics (NTLA) reported a Q1 2026 net loss of US$96.2 million on US$15.0 million revenue, similar to the previous quarter, raising questions about its path to profitability. Despite analysts projecting 64.4% annual earnings growth and profitability within three years, the company's premium P/S multiple of 29.6x and ongoing losses concern cautious investors. While a DCF fair value is significantly higher, this relies on future revenue growth and profitability, with continued dilution being a risk.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-quarterly-loss-near-us96-million

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia Therapeutics (NTLA) reported a narrower Q1 2026 loss per share of 81 cents, beating analyst estimates, although revenues of $15 million missed the mark. The company's stock has surged over 60% year-to-date. Intellia provided updates on its pipeline, including the lifting of FDA clinical holds for its nex-z program in ATTR amyloidosis and positive phase III results for lonvo-z in hereditary angioedema, with a BLA submission for lonvo-z expected in H2 2026.

https://www.tradingview.com/news/zacks:58ba8829a094b:0-ntla-q1-earnings-beat-estimates-revenues-miss-mark-pipeline-in-focus/

Intellia Therapeutics, Inc. (NTLA) reports Q1 loss, misses revenue estimates

Intellia Therapeutics, Inc. (NTLA) announced a Q1 loss of 99 cents per share, which was wider than the Zacks Consensus Estimate of a 91 cents loss per share. The company also reported revenue of $36.33 million, falling short of the Zacks Consensus Estimate of $50 million and showing a year-over-year decrease of 23.32%.

https://www.msn.com/en-us/money/topstocks/intellia-therapeutics-inc-ntla-reports-q1-loss-misses-revenue-estimates/ar-AA22V8cZ

Trending Today

Tezos ($XTZ) Crypto Forecast: Down 5.2% Today

Intellia Therapeutics, Inc. Price History

27.03.2026 - NTLA Stock was down 5.1%

• NTLA stock had a bearish movement despite positive late-stage trial data for its gene-editing therapy for hereditary angioedema (HAE).
• The market may have reacted negatively due to profit-taking by investors who were anticipating a bullish run following the positive trial results.
• Despite the positive news, the stock might have been impacted by the overall market sentiment or profit concerns, leading to the bearish movement.
• It's essential to consider that short-term market fluctuations do not always reflect the long-term potential of a company's innovative therapies.

29.03.2026 - NTLA Stock was down 10.0%

• Despite favorable late-stage trial outcomes and starting the FDA submission process for lonvoguran ziclumeran (lonvo-z) for HAE treatment, NTLA witnessed a decline in its stock value.
• The decrease in share price due to a public stock offering priced lower per share raised concerns about potential dilution among investors, impacting the company's stock performance negatively.
• Market sentiment may have been influenced by fears of share dilution from the public offering, overshadowing the encouraging trial results and future potential of gene-editing therapies.
• Investor hesitancy regarding the company's fundraising strategies and their effects on current shareholders prompted selling pressures, despite promising advancements in clinical research.

22.03.2026 - NTLA Stock was up 6.6%

• Analysts have given NTLA a moderate buy rating with an average price target of $21.25, indicating positive sentiment towards the company's future prospects.
• Despite recent share price volatility, the company's strong year-to-date and one-year performance, along with a narrative of rapid revenue growth, have contributed to the bullish movement.
• The market's interest in NTLA's valuation, driven by demographics and genetic conditions supporting its value, coupled with potential risks from trial disappointments or payer pushback, may have influenced the positive market sentiment.
• The amendment of by-laws and designation of federal district courts as the exclusive forum for Securities Act claims could also be seen as a positive development, enhancing shareholder rights and potentially boosting investor confidence in the stock.

14.04.2026 - NTLA Stock was down 9.8%

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

14.04.2026 - NTLA Stock was down 5.8%

• NTLA posted a Q1 2026 net loss of $96.2 million, which has sparked worries about its path to profitability and prompted a cautious response from investors.
• While exceeding earnings per share projections, the company fell short on revenue, reporting $15 million, leading to a downward trend in the market.
• The persistent losses, high price-to-sales ratio, and risks of dilution may have contributed to the prevailing bearish sentiment and decline in NTLA shares.
• Despite positive developments in its pipeline, such as successful Phase 3 outcomes for lonvo-z and the lifting of FDA clinical holds for nex-z trials, concerns about financial performance and short-term profitability seem to overshadow these advancements.

01.04.2026 - NTLA Stock was down 5.4%

• Despite successfully raising funds through a public equity offering and filing a Biologics License Application for lonvoguran ziclumeran (lonvo-z) after meeting Phase 3 endpoints, Intellia Therapeutics stock exhibited a bearish trend.
• The market reaction might be linked to investors resorting to profit-taking after having anticipated positive trial results and witnessing a subsequent sell-off as the news had already been factored into the stock price.
• Investor skepticism regarding the commercial potential of lonvo-z in comparison to existing effective therapies may have also influenced the downward movement, as concerns about future revenue generation linger.
• The surge in NTLA shares during pre-market trading following favorable late-stage trial data for lonvo-z possibly led to an overbought situation, causing a correction as traders capitalized on profits, ultimately resulting in the observed bearish movement today.

13.04.2026 - NTLA Stock was up 5.4%

• Despite reporting a significant Q1 loss, Intellia Therapeutics (NTLA) experienced a strong bullish movement in the stock market.
• The bullish movement can be attributed to the company's positive Phase 3 results for lonvo-z in hereditary angioedema (HAE) and the initiation of a rolling BLA submission for a potential U.S. launch in early 2027.
• Investors seem optimistic about Intellia's pipeline progress, including the lifting of FDA clinical holds for nex-z trials in ATTR amyloidosis, which indicates a promising future for the company's gene-editing programs.
• The market may also be reacting positively to Intellia's strategic reductions in R&D spending to focus on lead programs and commercial readiness, signaling a more efficient use of resources for future growth.

24.03.2026 - NTLA Stock was down 10.3%

• The bearish movement in NTLA stock today could be attributed to the following factors:
• Despite the recent positive momentum and market leadership demonstrated by Intellia Therapeutics, investors might be taking profits after a significant 20% increase in the stock price over the past three months.
• The mixed short-term returns and recent share price volatility, coupled with potential risks such as disappointing trial results or payer pushback on costs, could be causing some uncertainty among investors.
• While analysts have provided a moderate buy rating and set an average price target of $21.25, the discrepancy between the current share price and the estimated fair value according to a DCF model might be contributing to the downward pressure on the stock.
• Investors may also be cautious due to the company's amendment of its by-laws and the designation of federal district courts as the exclusive forum for Securities Act claims, which could introduce legal uncertainties impacting the stock's performance.

30.03.2026 - NTLA Stock was up 10.8%

• NTLA's stock surged after announcing the pricing of a public offering, raising significant gross proceeds and indicating investor confidence in the company's future prospects.
• The successful results of the Phase 3 trial for lonvo-z, Intellia's gene-editing medicine for hereditary angioedema (HAE), played a crucial role in driving up the stock price.
• The initiation of a rolling Biologics License Application submission to the FDA and the anticipation of a potential U.S. launch in the first half of 2027 further fueled positive investor sentiment.
• Overall, the combination of successful trial data, regulatory progress, and strong financial backing contributed to NTLA's bullish market movement today.

11.04.2026 - NTLA Stock was up 5.0%

• The bullish movement in NTLA's stock price can be attributed to the positive anticipation of beating earnings estimates, supported by a history of surpassing EPS estimates in previous quarters.
• The announcement of Intellia's participation in multiple investor conferences and fireside chats may have increased investor confidence in the company's strategic initiatives and future prospects.
• Cathie Wood's ARK Invest increasing its stake in NTLA could have also contributed to the bullish momentum, signaling confidence from a prominent investor in the biotech sector.
• Conflicting valuation metrics may have caused some volatility in the stock price, with investors potentially weighing the undervaluation suggested by the DCF model against the overvaluation indicated by the P/S ratio.

08.04.2026 - NTLA Stock was up 5.9%

• NTLA is expected to beat earnings estimates, with a positive Earnings ESP and a history of surpassing EPS estimates, indicating strong financial performance.
• A major investment firm increased its stake in NTLA, showcasing confidence in the company's future prospects and contributing to positive market sentiment.
• The announcement of NTLA's participation in upcoming investor conferences and positive Phase 3 results for its CRISPR gene editing therapy likely generated excitement among investors, driving the bullish movement in the stock.
• Overall, the combination of favorable financial outlook, increased institutional interest, and positive developments in its therapeutic pipeline propelled NTLA's stock price higher today.

12.04.2026 - NTLA Stock was down 7.0%

• NTLA stock's decline might be linked to the company's Q1 2026 financial figures, indicating a net loss of $96.2 million and lower revenue compared to the previous year.
• Despite achieving Phase 3 milestones for lonvo-z and progressing its gene-editing projects, investors possibly worried about NTLA's financial performance and the recent stock offering for additional funding.
• The difference in valuation assessments, with the DCF model suggesting undervaluation and the P/S ratio hinting at overvaluation, may have contributed to investor uncertainty, influencing the bearish movement.
• Overall, investor sentiment towards NTLA appears guarded today, considering the promise of its gene editing treatments alongside the company's financial struggles and valuation ambiguity.